Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline landscape. Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a ... Read More
-
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... or CD194 or CCR4) – C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor ... Read More
-
Calcitonin Gene Related Peptide (CGRP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of ... Read More
-
Huntingtin (Huntington Disease Protein or HTT) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022'; Huntingtin (Huntington Disease Protein or HTT) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. Huntingtin (Huntington Disease Protein or ... Read More
-
Sinusitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape. Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy ... Read More
-
Paroxysmal Nocturnal Hemoglobinuria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline landscape. Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier than normal. Symptoms include abdominal pain, ... Read More
-
Uveal Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Uveal Melanoma (Oncology) pipeline landscape. Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the ... Read More
-
Liver Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Liver Transplant Rejection (Immunology) pipeline landscape. Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability to regenerate or grow, unlike any ... Read More
-
Schistosomiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Schistosomiasis (Infectious Disease) pipeline landscape. Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes. Symptoms include a high temperature, headache, cough, a ... Read More
-
Hyperuricemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape. High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney ... Read More
-
Oligodendroglioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Oligodendroglioma (Oncology) pipeline landscape. Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, ... Read More
-
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Prolyl 4 hydroxylases (P4H) are iron- and 2-oxoglutamate-dependent dioxygenase enzymes and hypoxia-inducible transcription factor (HIF)-P4Hs play a critical role in ... Read More
-
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... According to the recently published report 'Nicotinamide Phosphoribosyl transferase – Drugs In Development, 2022'; Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) pipeline Target constitutes close to ... Read More
-
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Update Summary Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a ... Read More
-
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... published report 'Plasminogen Activator Inhibitor 1 – Drugs In Development, 2022'; Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 15 molecules. Out of which approximately 7 ... Read More
-
Leber Congenital Amaurosis (LCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the Leber Congenital Amaurosis (LCA) (Genetic Disorders) pipeline landscape. Leber congenital amaurosis is an eye disorder that primarily affects the retina, which is the specialized tissue at ... Read More
-
Acromegaly Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Acromegaly (Hormonal Disorders) pipeline landscape. Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive ... Read More
-
Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape. Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition ... Read More
-
Bacterial Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape. Bacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus sp, or, ... Read More
-
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... 1 or HPSE or EC 3.2.1.166) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Heparanase – Drugs In ... Read More
-
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... 2022 Update Summary High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) pipeline Target constitutes close to 9 molecules. Out of which approximately 5 molecules ... Read More
-
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Players, 2022 Update Summary Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) pipeline Target constitutes close to 7 molecules. Out of which approximately ... Read More
-
Celiac Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape. Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and ... Read More
-
Hemophilia B (Factor IX Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... In Development, 2022, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints ... Read More
-
Graft Versus Host Disease (GVHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... (GVHD) – Drugs In Development, 2022, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow ... Read More
Research Assistance
